In an adult with metabolic dysfunction‑associated steatotic liver disease (MASLD) without cirrhosis and no contraindications, can low‑dose aspirin (81 mg daily) be used for liver benefit and cardiovascular risk reduction, and what safety considerations apply?

Aspirin for MASLD: Liver and Cardiovascular Benefits

Low-dose aspirin (81 mg daily) can be used in adults with MASLD without cirrhosis for cardiovascular risk reduction when standard cardiovascular indications are met, and emerging evidence suggests potential direct liver benefit through reduction of hepatic fat content. 1

Direct Liver Benefits: Emerging Evidence

• A 2024 randomized controlled trial demonstrated that 6 months of aspirin 81 mg daily significantly reduced hepatic fat content by 10.2% absolute reduction (95% CI: -27.7% to -2.6%; P = 0.009) compared to placebo in adults with MASLD without cirrhosis. 1

• Aspirin treatment achieved a 30% or greater relative reduction in hepatic fat in 42.5% of patients versus only 12.5% with placebo (mean difference 30.0%; P = 0.006). 1

• The liver benefit was confirmed by both magnetic resonance spectroscopy and MRI proton density fat fraction, showing consistent reductions in hepatic steatosis across multiple measurement modalities. 1

• Aspirin may reduce hepatic inflammation, oxidative stress, and insulin resistance in hepatocytes, potentially preventing fibrosis progression in MASLD. 2

Cardiovascular Risk Reduction: The Primary Indication

The cardiovascular indication for aspirin in MASLD patients follows standard diabetes and cardiovascular guidelines, not liver-specific criteria. 3

When to Use Aspirin (Cardiovascular Indications):

• For secondary prevention: Aspirin 75-162 mg daily (typically 81 mg in the U.S.) is strongly recommended for adults with established atherosclerotic cardiovascular disease, regardless of MASLD status. 3, 4

• For primary prevention in select patients: Aspirin may be considered in adults aged 50-70 years with diabetes and at least one additional major cardiovascular risk factor (hypertension, dyslipidemia, smoking, family history of premature ASCVD, chronic kidney disease/albuminuria) who are not at increased bleeding risk. 3, 4

• The decision for primary prevention requires shared decision-making that carefully weighs cardiovascular benefits against bleeding risks, which are roughly comparable (approximately 5 per 1,000 per year for major bleeding). 3

When NOT to Use Aspirin:

• Adults over 70 years: The bleeding risk outweighs cardiovascular benefit for primary prevention in this age group. 3, 4

• Adults under 50 years without additional risk factors: Low baseline cardiovascular risk makes aspirin inappropriate. 3, 4

• Active bleeding, recent gastrointestinal hemorrhage, aspirin allergy, or concurrent therapeutic anticoagulation: These are absolute contraindications. 4

• Patients under 21 years: Risk of Reye syndrome contraindicates aspirin use. 3

Optimal Dosing

• Use 81 mg daily (the standard U.S. low-dose tablet) for both cardiovascular protection and potential liver benefit. 3, 4, 1

• Doses of 75-162 mg daily provide equivalent cardiovascular benefit to higher doses while minimizing gastrointestinal bleeding risk. 3

• The ADAPTABLE trial (38% participants with diabetes) showed no difference in cardiovascular events between 81 mg and 325 mg daily, confirming that lower doses are sufficient. 3, 4

Safety Considerations in MASLD

• Gastrointestinal bleeding risk: The most common adverse effect is increased gastrointestinal bleeding (approximately 5 per 1,000 per year in real-world settings). 3

• In the MASLD-specific trial, adverse events were similar between aspirin and placebo groups (32.5% each), with only one patient (2.5%) experiencing aspirin-related heartburn. 1

• Consider proton pump inhibitor co-therapy in patients with prior gastrointestinal bleeding, age >70 years, concurrent NSAIDs, anticoagulants, steroids, or chronic kidney disease. 5

• Anemia and renal disease increase bleeding risk and warrant careful assessment before initiating aspirin. 3

Integration with Comprehensive MASLD Management

Aspirin should complement, not replace, evidence-based MASLD therapies that address both liver disease and cardiovascular risk. 3

Priority Interventions:

• Lifestyle modification: Weight loss through dietary modification and physical activity remains the cornerstone of MASLD management. 3, 6

• Statin therapy: Statins can be used in adults with chronic liver disease, including compensated cirrhosis, and should be prescribed according to cardiovascular risk guidelines to reduce cardiovascular events (the leading cause of death in MASLD). 3

• Diabetes management: GLP-1 receptor agonists and SGLT2 inhibitors can be used in adults with Child-Pugh class A cirrhosis and provide metabolic benefits. 3

• Blood pressure control: ACE inhibitors or ARBs are recommended for patients with diabetes and hypertension to improve cardiovascular outcomes. 4

Clinical Algorithm for Aspirin Use in MASLD

1. Confirm MASLD diagnosis (hepatic steatosis with metabolic risk factors, no cirrhosis). 6

2. Assess cardiovascular risk:

   • If established ASCVD present: Start aspirin 81 mg daily (strong indication). 3, 4
   • If age 50-70 with diabetes plus ≥1 major cardiovascular risk factor: Consider aspirin 81 mg daily through shared decision-making. 3, 4
   • If age <50 or >70, or low cardiovascular risk: Do not use aspirin for primary prevention. 3, 4

3. Screen for contraindications: Active bleeding, aspirin allergy, therapeutic anticoagulation, age <21 years. 3, 4

4. Assess bleeding risk factors: Age >70, prior GI bleeding, anemia, renal disease, concurrent NSAIDs/anticoagulants. 3, 5

5. If aspirin is appropriate: Prescribe 81 mg daily and consider PPI co-therapy if bleeding risk factors present. 3, 4, 5

6. Monitor: Reassess bleeding risk at regular intervals, especially if anemia or gastrointestinal symptoms develop. 4

Common Pitfalls to Avoid

• Do not prescribe aspirin solely for liver benefit in MASLD: The primary indication remains cardiovascular risk reduction based on established guidelines; the liver benefit is an emerging secondary consideration. 3, 1

• Do not use higher doses (≥325 mg daily) for chronic therapy: This increases bleeding risk without additional cardiovascular or liver benefit. 3, 4

• Do not automatically prescribe aspirin to all patients with diabetes and MASLD: Age and additional cardiovascular risk factors determine appropriateness. 3, 4

• Do not overlook bleeding risk assessment: Older age, renal disease, and concurrent medications significantly increase bleeding complications. 3

• Do not neglect comprehensive MASLD management: Aspirin does not replace lifestyle modification, weight loss, statin therapy, and optimization of metabolic risk factors, which remain the foundation of care. 3, 6